cardiovascular outcomes

Pharma

FDA approves Lilly's Mounjaro to reduce risk of cardio events

The FDA has signed off on a label expansion for Eli Lilly's Mounjaro to reduce the risk of heart attack or stroke in at-risk adults with type 2 diabetes.

Kevin Dunleavy Aug 28, 2026 10:52am

Heart on futuristic podium with neon lighting

Wegovy tops Zepbound on CV risk reduction in real-world study

Sep 2, 2025 11:33am

Novo's oral semaglutide shows heart benefits

Oct 21, 2024 10:09am

Novo bolsters star power of obesity blockbuster Wegovy

May 14, 2024 11:40am

ESC says SGLT2s like Farxiga are first-line treatment in HF

Aug 28, 2021 1:35pm

Bayer's Kerendia racks up cardio benefits in outcomes trials

Aug 28, 2021 11:25am